Private astronaut mission marks next step toward a new space station
NASA is planning on decommissioning the International Space Station (ISS) by the end of 2030. But before that happens, Axiom Space, a privately funded space infrastructure company based in Houston, wants to build a replacement. The company has begun construction of the world's first commercial space station, Axiom Station.
But Axiom isn't waiting for their station to be completed before transporting people into space. The company has been launching teams of private astronauts to the ISS since 2022, allowing them to conduct research, train, and participate in scientific activities. And on Wednesday at 8 a.m., Axiom Space will attempt to send its fourth crew to the ISS as part of its AX-4 mission.
"The AX-4 crew represents the very best of international collaboration, dedication, and human potential. Over the past 10 months, these astronauts have trained with focus and determination, each of them exceeding the required thresholds to ensure mission safety, scientific rigor and operational excellence," said Allen Flynt, Axiom Space's chief of mission services, during a pre-launch press conference on Monday.
The four-person crew will lift off from Launch Complex 39A at NASA's Kennedy Space Center in Florida and travel to the ISS aboard a SpaceX Dragon spacecraft launched into orbit by a Falcon 9 rocket. It will be the maiden mission for an updated Dragon capsule.
MORE: A private company wants to build a city on the moon. But it has to land a probe first
"This is the first flight for this Dragon capsule, and it's carrying an international crew—a perfect debut. We've upgraded storage, propulsion components and the seat lash design for improved reliability and reuse," said William Gerstenmaier, SpaceX's vice president of build and flight reliability.
The mission will be led by Peggy Whitson, a former NASA astronaut and the director of human spaceflight at Axiom. During her career at NASA, Whitson completed three long-duration space flights, spending a total of 665 days in orbit. She also commanded Axiom's AX-2 mission, adding another 10 days in space to her already impressive total. Whitson now holds the record for the most time spent in space by a woman.
"We're thrilled to welcome Peggy Whitson back. This will be her fifth trip to space—three with NASA and now two with Axiom," Dana Weigel, NASA's manager of the International Space Station Program, said. "She's made substantial contributions to ISS and now helps lay the foundation for future commercial missions."
Joining Whitson on the AX-4 mission are astronauts from India, Poland and Hungary. This will be the first time that nationally sponsored astronauts from those countries have visited the ISS. It has also been more than 40 years since those three countries sent someone into space.
MORE: New Biomass satellite will provide an unprecedented look at the planet's forests
Indian Air Force pilot and astronaut Shubhanshu Shukla, the mission's pilot, will be the second person from India to go to space and the first since 1984. Polish engineer Sławosz Uznański, a mission specialist and a European Space Agency project astronaut, will be the second person from his country to head to space and the first since 1978. And Tibor Kapu, a mechanical engineer and mission specialist, will be the second Hungarian astronaut to rocket into space. That country's last space mission was 45 years ago.
"For India, Poland, and Hungary, this mission marks a return to human spaceflight after more than 40 years, and their first missions to the ISS. It's a powerful reminder of what we can achieve when we work together across borders, disciplines, and cultures," Flynt said.
The AX-4 mission will last up to 14 days, during which the crew will conduct about 60 scientific studies and experiments. The company said 31 countries have contributed to the research plan and that the projects will focus on biological, life and material sciences, as well as Earth observation. Axiom said that the work done at the station will help the company advance its goal of building Axiom Station, which would be the world's first commercial space station.
To lay the foundation for its space station, Axiom plans to attach several of its commercial modules to the ISS while it's still operational. When the ISS is decommissioned, those modules will detach from the station and become part of the privately run Axiom Station.
Unlike space tourism, which is operated independently of NASA and government support, the Axiom mission is part of NASA's private astronaut mission program. This private-public partnership provides selected commercial space companies with access to the ISS and technical and logistical support from NASA.
"NASA's framework for private astronaut missions gives industry responsibility for launch, free flight, and landing," Weigel said.
"It's an incredible time for spaceflight. These missions help train teams, build partnerships and shape the future of low Earth orbit," she added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NASA raises the odds that an asteroid could hit the moon in 2032
When you buy through links on our articles, Future and its syndication partners may earn a commission. Asteroid 2024 YR4, once considered the highest impact risk to Earth ever recorded, is back in the spotlight — this time due to a slight increase in the chance that it could impact the moon in 2032. Although now too distant to observe from Earth, the asteroid briefly came into view in May for the James Webb Space Telescope (JWST). Using data from the telescope's Near-Infrared Camera, a team led by Andy Rivkin of the Johns Hopkins Applied Physics Laboratory refined predictions of where 2024 YR4 will be on Dec. 22, 2032 by nearly 20%. That revised trajectory nudged the odds of a lunar impact from 3.8% to 4.3%, according to a NASA update. "As data comes in, it is normal for the impact probability to evolve," the statement read. Even if a collision occurs, "it would not alter the moon's orbit." Astronomer Pawan Kumar, a former researcher at the Indian Institute of Astrophysics in Bengaluru, agrees the moon is safe, noting a collision with the moon "won't be a cause for concern" because any moon debris blasted into space from the impact "blow up in Earth's atmosphere if any of it makes it to near-Earth space." First detected on Dec. 27 last year, 2024 YR4 is estimated to be about 174 to 220 feet long (53 to 67 meters), or about the size of a 10-story building. The asteroid quickly grabbed headlines for having more than a 1% chance of striking Earth, the highest recorded for any large asteroid. Follow-up observations in January and February saw the impact risk climb from 1.2% to a peak of 3.1%. The asteroid's projected trajectory at the time suggested it could cause blast damage across a wide potential impact zone, spanning the eastern Pacific, northern South America, Africa and southern Asia. If it enters Earth's atmosphere over the ocean, NASA estimated it would be unlikely to trigger significant tsunamis, but an airburst over a populated city could shatter windows and cause minor structural damage. However, the impact risk dropped sharply as additional orbital data came in. By Feb. 19, the probability had fallen to 1.5%, and then to 0.3% the next day. On Feb. 24, NASA announced an official "all clear" on social media, reporting the impact probability had dropped to just 0.004% and that the asteroid is "expected to safely pass by Earth in 2032." Further analysis has since allowed scientists to rule out any risk to Earth, not only in 2032 but from all future close approaches as well. Data from telescopes in Chile and Hawaii recently suggested the space rock originated in the central main belt between Mars and Jupiter and gradually shifted into a near-Earth orbit. Since mid-April, the asteroid has been too far away and too faint to be seen from Earth. It will swing back into view in 2028, giving scientists another chance to observe the asteroid and further refine its orbit using both JWST and ground-based telescopes. In particular, scientists will aim to gather more data on its shape and composition, which are key factors in understanding both its behavior and potential impact effects. RELATED STORIES — Odds of an asteroid impact in 2032 just went up. Here's why experts say you shouldn't worry — Asteroid apocalypse: How big must a space rock be to end human civilization? — Astronomers discover 196-foot asteroid with 1-in-83 chance of hitting Earth in 2032 While 2024 YR4 no longer poses any danger, it provided scientists with a rare, real-world opportunity to rehearse the full scope of planetary defense strategy, ranging from initial detection and risk analysis to public messaging. It was "an actual end-to-end exercise" for how we might respond to a potentially hazardous asteroid in the future, said Kumar. "2024 YR4 is a tailor-made asteroid for planetary defense efforts," he said. "It has everything it takes to get our attention."
Yahoo
3 hours ago
- Yahoo
Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025. The EHA Annual Congress is the largest gathering of the hematology community in Europe. Attracting more than 10,000 attendees from more than 100 countries every year, the congress showcases cutting-edge research and ground-breaking clinical results in the field of hematology. Oral PresentationIntegrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy Abstract#: S162 Session: Biology of CML treatment response and resistance Date and Time: Saturday, 14 June, 17:30-17:45 CEST / Saturday, 14 June, 23:30-23:45 Beijing Time Principal Authors: Prof. Qian Jiang, Peking University People's Hospital; Dr. Xiaoshuai Zhang, Peking University People's Hospital Poster PresentationsFrontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study Abstract#: PF384 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Author: Prof. Xiaowen Tang, The First Affiliated Hospital of Soochow University; Xin Zhang, The First Affiliated Hospital of Soochow University A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Abstract#: PF390 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Suning Chen, The First Affiliated Hospital of Soochow University; Wenzhi Cai, The First Affiliated Hospital of Soochow University Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia Abstract#: PS1367 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Hongsheng Zhou, Nanfang Hospital, Southern Medical University; Xiuli Xu, Nanfang Hospital, Southern Medical University Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial Abstract#: PS1372 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Jie Jin, The First Affiliated Hospital, Zhejiang University School of Medicine; Dr. Gaixiang Xu, The First Affiliated Hospital, Zhejiang University School of Medicine Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study Abstract#: PS1387 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Author: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Xiaoyu Zhang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models Abstract#: PS1993 Session: Lymphoma biology & translational research Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Principal Author: Dr. Eric Liang, Ascentage Pharma Group Inc. Online PublicationsAlternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis Abstract: PB2384 Principal Author: Prof. Zi-Yuan Nie, The Second Hospital of Hebei Medical University Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive/Negative B-Cell Acute Lymphoblastic Leukemia Abstract#: PB2363 Principal Author: Yinqiang Zhang, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Abstract#: PB2360 Principal Author: Xinwen Jiang, The Second Hospital of Hebei Medical University Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study Abstract#: PB2701 Principal Author: Mengyao Yuan, Peking University People's Hospital A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study Abstract#: PB2714 Principal Author: Tian Dong, West China Hospital of Sichuan University Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Abstract#: PB2341 Principal Author: Bo Peng, Ascentage Pharma (Suzhou) Co., Ltd. About Ascentage PharmaAscentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML, and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
12-mile-tall volcano on Mars punches through clouds
When you buy through links on our articles, Future and its syndication partners may earn a commission. A bit after sunrise on June 6, 2025, NASA's 2001 Mars Odyssey orbiter saw one of Mars' biggest volcanoes, Arsia Mons, as it broke through the clouds. The volcano is the cloudiest of the Tharsis volcanoes, a trio that is tightly aligned on Mars' surface. Standing at over 12 miles (20 kilometers) with a diameter of 270 miles (450km), Arsia Mons is nearly twice as high as Mauna Loa, Earth's largest volcano, which sits at 6 miles (9 kilometers) from the seafloor. Due to its height, Arsia Mons is often covered by clouds that form when expanded air that was blown up the sides of the volcano rapidly cools. These clouds can be especially thick during aphelion, a period where Mars is farthest from the sun in its orbit. Clouds that form during this time at the planet's equator are known as the aphelion cloud belt, according to NASA. Arsia Mons is the southernmost volcano in a trio called the Tharsis Montes, or the Tharsis mountains, which are located in Mars' western hemisphere near its equator. The alignment of the Tharsis volcanoes suggests that a large fracture may have been responsible for the eruptions that formed all three volcanoes, according to NASA's Jet Propulsion Laboratory (JPL). To the northwest of the group stands Olympus Mons, the biggest volcano in the solar system, at 16 miles (25 kilometers) high. Because of its cloud cover, Arsia Mons has been hard to photograph. This new image from NASA's 2001 Mars Odyssey orbiter gives a first-of-its kind view at the peak of the volcano. The picture is also the first time any of the three Tharsis volcanoes has been captured on the horizon, offering a similar perspective as what astronauts see from the International Space Station when they view Earth, according to NASA. Unlike other regions of the planet, the clouds that surround this volcano are made of water ice, which remains in Mars' atmosphere most of the year. In fact, the Martian atmosphere contains more water vapor than the upper layers of Earth's atmosphere, according to JPL. Other areas of Mars contain dust storms made of carbon dioxide clouds. Studying these cloud formations helps experts to better understand how storms form and occur on the Red Planet. You can read more about Martian volcanoes and cloud storms as scientists dive further into the features of our planetary neighbor.